Gastric Cancer: Nagoya Is Not New York

Macdonald, John S.

doi:10.1200/jco.2011.37.5691

Cited by 29 publications

(18 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When it comes to GC, a significant geographic variation in the incidence exists, with the highest rates being reported in East Asian countries [26], including Korea, China and Japan. In Korea and Japan, where mass screening is performed widely, early detection is often possible [27].…”

Section: Discussionmentioning

confidence: 99%

Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer

Kim

Lee²,

Choi³

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Based on our previous studies, differential analysis of N-glycan expression bound on serum haptoglobin reveals the quantitative variation on gastric cancer patients. In this prospective case-control study, we explore the clinically relevant glycan markers for gastric cancer diagnosis. Serum samples were collected from patients with gastric cancer (n = 44) and healthy control (n = 44). N-glycans alteration was monitored by intact analysis of Hp using liquid chromatography–mass spectrometry followed by immunoaffinity purification with the serum samples. Intensity and frequency markers were defined depending on the mass spectrometry data analysis. Multiple markers were found with high diagnostic efficacy. As intensity markers (I-marker), six markers were discovered with the AUC > 0.8. The high efficiency markers exhibited AUC of 0.93 with a specificity of 86% when the sensitivity was set to 95%. We additionally established frequency marker (f-marker) panels based on the tendency of high N-glycan expression. The AUC to conclude patients and control group were 0.82 and 0.79, respectively. This study suggested that N-glycan variation of serum haptoglobin were associated with patients with gastric cancer and might be a promising marker for the cancer screening.

show abstract

Section: Discussionmentioning

confidence: 99%

Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer

Kim

Lee²,

Choi³

et al. 2016

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Whilst in Japan were excellent treatment results reached with single modality of D2 dissection with actually better results than those of combined modality approach in western countries, the usefulness of D2 over D1 lymph node dissection in western part of the world is still under discussion and its possible benefit was proved quite recently [12,13]. These differences reflect a different epidemiology and perhaps a different etiology of gastric cancer around the world [14]. Instead of these contrasts, it is clear that surgery remains a mainstay of the gastric cancer treatment.…”

Section: Discussionmentioning

confidence: 99%

Toxicity and survival outcomes of adjuvant chemoradiation for gastric and gastroesophageal junction cancer patients treated in period 2006-2009: an institutional experience.

Slavík

Burkoň²,

Kazda³

et al. 2014

neo

View full text Add to dashboard Cite

Surgical resection is the mainstay of gastric or gastroesophageal junction cancer treatment and has curative potential for patients with early-stage disease. In order to improve the poor survival rates, there are two complementary treatment strategies used at most -perioperative chemotherapy based on UK Magic trial or adjuvant chemoradiation based on INT-0116 trial. Daily treatment decision making should be led also by institutional experiences with toxicity evaluation. We evaluated survival and toxicity outcomes of 47 consecutive patients who underwent adjuvant chemoradiation in our institution in the years 2006-2009 in 5 weeks with concurrent two cycles of FUFA Mayo regimen chemotherapy were administrated as part of combined treatment. The acute toxicity was relatively mild (CTCAE scale): grade 2 nausea in 26%, vomiting in 13%, and diarrhoea grade 1 in 15% and general abdominal discomfort in 57% of patients. Grade 3 haematological and infectious complications in 6% and 2% respectively. Late adverse events were as follows: grade 1 esophageal toxicity in 17%, signs of mild chronic esophageal ulceration and esophageal stenosis in 9% of patients (50% of them had tracheoesophageal fistula). The Kaplan-Meier estimate of the median overall survival was 30.5 months with median 25.7 months disease free survival. The overall survival was statistically significantly affected by the amount of removed positive lymph nodes. For the proper evaluation of radiotherapy role in multimodal treatment approach, results of other clinical trials investigating role of concurrent radiotherapy in administration of perioperative chemotherapy will be necessary. Meanwhile, two equally approaches are possible, all having their pros and cons. Institutional toxicity evaluation is recommended in order to provide the best care possible.

show abstract

“…Although this is a considerable 5-year survival rate, it is important to analyze the data with caution. First, the CLASSIC trial was performed exclusively in western countries, and GC has different characteristics among different populations [19]. For example, among Asian populations, GC is more associated with the distal organ, which is different from western populations, in which GC is more associated with the gastroesophageal junction and proximal stomach.…”

Section: Treatment Methods For Gcmentioning

confidence: 99%

Treating Operable Patients with Gastric Cancer: Macdonald’s Protocol Versus Adjuvant Chemotherapy

et al. 2015

View full text Add to dashboard Cite

Gastric Cancer: Nagoya Is Not New York

Cited by 29 publications

References 14 publications

Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer

Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer

Toxicity and survival outcomes of adjuvant chemoradiation for gastric and gastroesophageal junction cancer patients treated in period 2006-2009: an institutional experience.

Treating Operable Patients with Gastric Cancer: Macdonald’s Protocol Versus Adjuvant Chemotherapy

Contact Info

Product

Resources

About